RedHill Biopharma (RDHL) Common Equity (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Common Equity data on file, last reported at $4.3 million in Q4 2025.

• On a quarterly basis, Common Equity rose 191.14% year-over-year to $4.3 million in Q4 2025; TTM through Dec 2025 was $4.3 million, a 191.14% increase from a year earlier, with the FY2025 full-year figure at $4.3 million, up 191.14% from the prior year.
• Common Equity for Q4 2025 stood at $4.3 million, up from -$4.4 million in the prior quarter.
• Over the last five years, Common Equity for RDHL reached as high as $53.0 million in Q1 2021 and fell as low as -$48.4 million in Q4 2022.
• Historically, Common Equity has averaged -$866230.8 across 5 years, with a median of $61000.0 in 2024.
• On a YoY basis, Common Equity climbed as much as 191.14% in 2025 and fell as far as 7332.79% in 2025.
• Year by year, Common Equity stood at $8.9 million in 2021, then sank by 645.35% to -$48.4 million in 2022, then jumped by 104.27% to $2.1 million in 2023, then slumped by 326.34% to -$4.7 million in 2024, then jumped by 191.14% to $4.3 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $4.3 million in Q4 2025, -$4.4 million in Q2 2025, and -$4.7 million in Q4 2024.